Compare ACXP & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACXP | ORIS |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 4.6M |
| IPO Year | 2021 | 2024 |
| Metric | ACXP | ORIS |
|---|---|---|
| Price | $4.40 | $0.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $143.67 | N/A |
| AVG Volume (30 Days) | 80.1K | ★ 2.4M |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $12,317,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $545.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.17 | $0.08 |
| 52 Week High | $25.00 | $3.17 |
| Indicator | ACXP | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 43.66 |
| Support Level | $3.17 | $0.11 |
| Resistance Level | $3.50 | $0.13 |
| Average True Range (ATR) | 0.42 | 0.01 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 88.08 | 45.52 |
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).